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Background: Early diagnosis of immune heparin-induced thrombocytopenia (HIT) is essential to improve clinical
outcome but remains challenging. The release of platelet microparticles (PMPs) is considered of major patho-
physiological signiﬁcance.
Objectives: The aim of this study was to evaluate performances of PMP generation assay (PMPGA) compared
to clinical outcome to diagnose HIT. The second objective was to compare PMPGA with performances of
14C-serotonin release assay (SRA) on the same series of patients.
Methods: Sera of 53 HIT-suspected patients were retrospectively incubated with citrated-whole blood from
healthy donors with 1 IU and 500 IU/ml of unfractionated heparin (UH). PMPGA was performed using
FACSAria® ﬂow cytometer. The clinical diagnosis was established by two blinded independent investiga-
tors analysing in a standardized manner the patient’s medical records. Performances of PMPGA and SRA
(n = 53) were evaluated using ROC curve analysis with clinical outcome as reference.
Results: In positive HIT patients, PMPs expressing phosphatidylserine are generatedwith lowUH concentra-
tion whereas PMP rate decreases signiﬁcantly in presence of high UH concentration. Using clinical outcome
as reference, sensitivity and speciﬁcity of PMPGA reached 88.9% (95% CI: 50.7-99.4) and 100.0% (95% CI:
90.0-100.0). Sensitivity and speciﬁcity of 14C-SRA were 88.9% (95% CI: 50.7-99.4) and 95.5% (95% CI:
83.3-99.2).
Conclusions: PMPGA is a rapid and reliable assay for HIT diagnosis. PMPGA showed good correlation with
14C-SRA performances and predominately with clinical outcome.© 2013 Elsevier Ltd. All rights reserved.Introduction
Immune heparin-induced thrombocytopenia (HIT) is a severe
immune-mediated adverse effect of heparin treatment that can result
in potentially life-threatening conditions such as venous or arterial
thrombosis. Venous thrombosis in HIT patients is four-fold more com-
mon than arterial thrombosis [1]. HIT consists of an immune response
leading to platelet activation, platelet aggregation, production and
release of procoagulant platelet microparticles (PMPs), activation of
monocytes, endothelial cells andﬁnally to thrombin generation. Platelet
activation by pathogenic anti-platelet factor 4 (PF4)-heparin antibodies
generates PMPs. Moreover, PMPs serve as a catalytic surface for
enhanced thrombin generation, considered as a major component ofRILIS, CHU Dinant-Godinne UCL




org/10.1016/j.thromres.2013.this reaction [2,3]. These PMPs are characterised by a size ranging
from 0.1 μm to 1.0 μm, and by membrane expression of glycoprotein
Ib (GPIb, CD42b) and integrin αIIbβ3 (GPIIb-IIIa, CD41/CD61) [4].
Early diagnosis of HIT is essential to improve clinical outcomes.
However, this diagnosis remains challenging. The current diagnostic
approach consists of the combination of the clinical scoring system
(“4Ts score”) with immunoassays and functional tests [2,5,6]. Immuno-
assays [polyspeciﬁc antigen assays (IgG/A/M)and the IgG-speciﬁc enzyme-
immunoassay (EIA)] are acceptable to rule out HIT [2] but are still lacking
speciﬁcity [7] and need standardization of optical density ranges [8].
Heparin-induced platelet aggregation (HIPA) and 14C-serotonin release
assay (14C-SRA) are considered as reference functional assays [9,10]. How-
ever, 14C-SRA is time-consuming, technically demanding and requires
radioactivity. In addition, this assay is not easily available in routine clinical
laboratories and is therefore seldom available to clinicians in real time.
Inter-laboratory variability and lack of standardization are also of concern
[11,12]. A previous study reported approaches to perform quality control
of the SRA [13].assay: A valuable test for immune heparin-induced thrombocytopenia
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2 F. Mullier et al. / Thrombosis Research xxx (2013) xxx–xxxThe validation of a newgold standard assaywould be useful to avoid
misdiagnosis [11] and overdiagnosis [14].
We have recently developed a PMP generation assay (PMPGA) in
whole blood that could be routinely used for diagnosis of HIT [15].
This assay was not compared with clinical outcome. In the present
larger study, we compared PMPGA with SRA and clinical outcome. The
ultimate goal is to provide a validated easy to use and rapid functional




Healthy platelet donors did not take any drug potentially affecting
the platelet function for 10 days before the blood sampling.
Patients
After approval by the local ethical committee, 57 patients with
suspected diagnosis of HIT at CHU Dinant-Godinne UCL Namur were
included in this study. HIT was suspected because of a rapidly decreas-
ing platelet count occurring in hospitalised patients under heparin
therapy.
4Ts score and clinical diagnosis
Following HIT suspicion, the “4Ts score” was calculated (based on
four criteria: the severity of the thrombocytopenia and its timing, the
occurrence of a thrombosis and the exclusion of other causes of throm-
bocytopenia) [16]. Clinical data were recorded in real time in the
hospital medical database. The following information was taken into
consideration: patient’s medical history, types (fractionated vs.
unfractionated) and doses of heparin administered, thrombotic compli-
cations, alternative diagnoses, therapeutic attitude, clinical and platelet
count evolution, co-suspected medications, and physician’s diagnoses
[6,17].
Complete compression ultrasonography and multidetector spiral
computed tomography were performed for suspected thrombosis.
Patients were classiﬁed as positive or negative HIT according to clin-
ical outcome. Clinical outcome were retrospectively and independently
conﬁrmedby two investigators (VMand FM), not aware of the results of
the laboratory assays. Several clinical criteria have to be fulﬁlled for the
conﬁrmation of clinical HIT diagnosis. Criteria from the ACCP (American
College of Chest Physicians) guidelines were used to make the clinical
diagnosis of HIT: (i) Thrombocytopenia, deﬁned as at least a 30% decline
in the platelet count, with a platelet count increase after heparin cessa-
tion; (ii) Timing of platelet count fall after the initiation of heparin
occurring between 4 and 14 days, or occurring within 24 to 48 hours
(in case of prior heparin exposure within 30 days); and (iii) lack of
other, predominant causes of thrombocytopenia [18]. Other causes of
thrombocytopenia analysed in this studywere: neoplasia, current preg-
nancy or postpartum, autoimmune disease, sepsis, disseminated intra-
vascular coagulation, intra-aortic balloon pump counterpulsation,
multitransfusion, multi-trauma, shock syndrome and drug-induced
thrombocytopenia (quinolone, β-lactam, vancomycin, teicoplanin,
rifampicin, isoniazid, amphotericin, ﬂuconazole, chemotherapy, anti-
GPIIb IIIa; furosemide and proton pump inhibitor). All those 3 clinical
criteria have to be fulﬁlled for the conﬁrmation of clinical HIT diagnosis.
Clinical diagnoses made by the 2 local investigators were 100% concor-
dant among them and with conclusions of the medical database.
Blood sampling and handling
Brieﬂy, blood was collected with a 20 gauge needle via atraumatic
antecubital venipuncture into polyethylene tubes terephtalate Venosafe®Please cite this article as: Mullier F, et al, Platelet microparticle generation
diagnosis, Thromb Res (2013), http://dx.doi.org/10.1016/j.thromres.2013(Terumo Europe, Leuven, Belgium) containing buffered sodium citrate
(109 mM, nine parts blood to one part sodium citrate solution). A discard
tube was used to avoid thromboplastin contamination.Laboratory testing
PMPGA and 14C-SRA were performed retrospectively on frozen
(−80 °C for maximum 18 months) sera.Platelet microparticle generation assay (PMPGA)
The PMPGA was performed on the 53 HIT-suspected patients who
completed the clinical follow-up.
Brieﬂy, 150 μl of sera of HIT-suspected patients were ﬁrst incubated
20 minutes at 37 °C with 165 μl of citrated 109 mMwhole blood from
one appropriate healthy donor (group O Rh + or isogroup ABO and
Rh)with 1 IUunfractionated heparin (UH)/ml and 500 IUUH/ml. Plate-
let microparticles (PMPs) are positive for antiCD41-PE. PMPs negative
for annexin-V FITC (phosphatidylserine (PS)) (Fig. 1, Q1) and PMPs pos-
itive for annexin-V FITC (Fig. 1, Q2), were quantiﬁed on a BDIS FACS
Aria® ﬂow cytometer (BD Biosciences, San Jose, CA, USA). The gating
strategy involves the following gates: the size of the MPs was deﬁned
using a blend of monodisperse ﬂuorescent beads (Megamix, BioCytex,
Marseille, France) of three diameters (0.5, 0.9 and 3 μm) according to
a previously described protocol [19,20]. The threshold was set on the
forward scatter according to ISTH recommendations [19]. In addition,
the threshold on side scatter (SSC) was set at the lower limit (i.e.
200 AU). Then, the CD41-Annexin V gate was applied on the MP
area for detecting platelet MPs expressing PS (PMPs PS+). After di-
viding the PE/FITC plot into four quadrants, CD41/PS + MPs would
appear in the upper right quadrant. The acquisition started only
after one minute to ensure ﬂuidics stability. Flow rate and acquisi-
tion time were recorded to calculate the PMP concentration in the
samples.
PMP concentrations were measured with 1 IU UH/ml and with
500 IU UH/ml to determine, respectively, PMP concentration gener-
ated by HIT antibodies and to check the speciﬁcity. Results of PMPGA
are expressed as the ratio between PMP annexin V positive (Q2) con-
centration generated with 1 IU UH/ml and 500 IU UH/ml (rule 1)
and as the concentration of PMPs annexin V positive (Q2) generated
at 1 IU UH/ml (rule 2).
The ﬂow rate was determined by recording during 10 minutes a
knownnumber of beads included in a TruCount® tube (BD biosciences).
This tube contains a mix of serum and whole blood of a healthy subject
(in proportionsmentioned above). The aimwas to have a similar viscos-
ity index that in the test sample. Themeasurementwas performed each
60 sec until 10 minutes with a coefﬁcient of variation lower than 10%.14C-serotonin release assay
The 14C-serotonin release assay was carried out according to previ-
ously published protocols on the 53 HIT-suspected patients who com-
pleted the clinical follow-up [6,10].Data analysis
Statistical analysis was performed using Medcalc software (version
10–4.8) (Gent, Belgium).
ROC Curves were performed to determine the optimal cut-offs of
PMPGA for rule 1 and rule 2 compared to clinical outcome. When indi-
cated, comparison of ROC Curves was also performed.
Area under the curve, sensitivity and speciﬁcity of PMPGA (rule 1,
rule 2, rule 1+2), 14C-SRA and their 95%CIwere calculatedwith clinical
outcome as reference.assay: A valuable test for immune heparin-induced thrombocytopenia
.12.009
Fig. 1. Comparison of PMP concentration generated with 1 IU UH/ml and 500 IU UH/ml. A, B) HIT patient: ratio between PMP annexin V positive concentration generated with 1 IU







3F. Mullier et al. / Thrombosis Research xxx (2013) xxx–xxxResults
Among the 57 patients, 53 completed the clinical follow-up and 4
patients were excluded of the study because of lack of clinical data. 35
males and 18 females aged from 24 to 97 years were included in this
study (mean: 65 years, median: 66 years) (53 inpatients and 0 outpa-
tients; 31 surgical and 22medical patients). Nine (17%)were diagnosed
HIT by clinical diagnosis. According to the 4Ts score, the 53 patients in-
cluded in the study were classiﬁed as low (n = 24; 45%), medium
(n = 22; 42%), and high pre-test probability (PTP) (n = 7; 13%).
Platelet activation by immune complexes IgG-PF4-heparin gener-
ates PMPs expressing phosphatidylserine during PMPGA. As shown in
Fig. 1, the PMPGA assay is based on the ratio between PMP annexin V
positive concentration generated with 1 IU UH/ml and 500 IU UH/ml
(rule 1: PMPs PS + ratio) and the concentration of PMPs annexinVpos-
itive generated at 1 IU UH/ml (rule 2: PMPs PS + concentration).Please cite this article as: Mullier F, et al, Platelet microparticle generation
diagnosis, Thromb Res (2013), http://dx.doi.org/10.1016/j.thromres.2013.Comparison of PMPGA to the clinical outcome (n = 53 including 9 positive
HIT patients)
The optimal cut-off for rule 1 and rule 2 induced by 1 IU heparin/ml
were 2.4 and 4,835 MPs/μl, respectively. Within positive patients, the
mean MPs concentration measured with 1 IU heparin/ml was 10,756
MPs/μl (range: 2,246- 22,610 MPs/μl) and the mean speciﬁcity ratio
was 10.1 (range: 3.5-32.0). In the negative patient group, the mean
MPs concentration measured with 1 IU heparin/ml was 2,204 MPs/μl
(range: 434–12,628 MPs/μl) and the mean speciﬁcity ratio was 1.1
(range: 0.5-2.4).
When rule 1 is taken into account, AUC, sensitivity and speciﬁcity
were 0.989 (95% CI: 0.911-0.995), 100.0% (95% CI: 62.9-100.0)
and 97.7% (95% CI: 86.5-99.9), respectively. When rule 2 is taken
into account, AUC, sensitivity and speciﬁcity were 0.933 (95% CI:
82.9 -98.3), 88.9% (95% CI: 51.7-98.2) and 97.7% (95% CI: 86.5-
99.9), respectively.assay: A valuable test for immune heparin-induced thrombocytopenia
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Table 1
Comparison of PMPGA (rule 1, rule 2, rule 1 + rule 2), 14C-SRA with the clinical outcome. Only data from patient with available PMPGA, 14C-SRA and clinical outcome, were considered
(n = 53).
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4 F. Mullier et al. / Thrombosis Research xxx (2013) xxx–xxxWhen both rules are considered, AUC, sensitivity and speciﬁcity
were 0.944 (95% CI: 0.845-0.988), 88.9% (95% CI: 50.7-99.4) and
100.0% (95% CI: 90.0-100.0%), respectively. (Table 1).
When comparing ROCCurves for “rule 1″, “rule 2″ and “rule 1 + rule
2″, the AUCwere not statistically different between “rule 1″ and “rule 2″
(p-value: 0.142) and “rule 1″ and “rule 1 + rule 2″ (p-value: 0.436).
However, the AUC was signiﬁcantly higher for “rule 1 + rule 2″ in
comparison to “rule 2″ (p-value: 0.038).
Comparison of SRA to the clinical outcome (n = 53 including 9 positive
HIT patients)
AUC, sensitivity and speciﬁcity of SRA were 0.922 (95% CI: 81.4 –
97.7), 88.9% (95% CI: 50.7-99.4) and 95.5% (95% CI: 83.3-99.2).
Comparison of PMPGA and 14C-SRA
PMPGA (rule 1 and 2) presented 1 false negative. SRA presented 2
false positives and 1 false negative. Four discordant cases between
PMPGA and SRA are shown in Table 2 (patient 1–4).
Patient 1 had a 4Ts score of 3 with negative immunoassay and light
transmission aggregometry (LTA). Patient 2 had a 4Ts score of 4 with
negative immunoassay and positive LTA. She received low-molecular-
weight heparin for more than 3 months and thrombocytopenia worsed
after switching to danaparoid and hirudin. Platelet count normalized
after treatment of pneumonia Klebsiella oxytoca pneumonia by ceftazi-
dime. Patient 3 had a 4Ts score of 6with positive immunoassay and pos-
itive LTA. She developed thrombosis after heparin administration and
her platelet count normalized within 5 days after heparin cessation.
Finally, patient 4 had a 4Ts score of 5 with positive immunoassay (opti-
cal density = 1.5) and positive LTA. After heparin cessation, his platelet
count normalized within one week.
Discussion
In this study, we compared the performances of the PMPGA and
14C-SRA to the clinical outcome to diagnose HIT. As a surface areaTable 2
Clinical and laboratory data for the 9 patients with a positive diagnosis of HIT and the 2 non H
Patient Laboratory assays Clinical data
PMPGA
rule 1 + 2
SRA 4Ts score Clinical evolution from the H
Stop heparin Platelet
1 - + 3 - -
2 - + 4 + -
3 + - 6 + +
4 - + 5 + +
5 + + 5 + ND (dea
6 + + 7 + +
7 + + 6 + +
8 + + 6 + +
9 + + 8 + +
10 + + 4 + +
11 + + 6 + +
Please cite this article as: Mullier F, et al, Platelet microparticle generation
diagnosis, Thromb Res (2013), http://dx.doi.org/10.1016/j.thromres.2013unit of PMP has approximately 50- to 100-fold higher procoagulant
properties than an identical surface area unit of an activated platelet
[21], PMPs is a more relevant biomarker than activated platelets
[22,23]. Other ﬂow cytometry tests mainly based on the detection
of activated platelets [22,23] were already proposed for the diagnosis
of HIT. A test based on PMPs was described in 1996 [24]. However, it
was limited by several issues: i) it was performed on the FACScan, an
old generation FCMr non validated for large MP analysis [19], ii) the
size of MPs was not calibrated making impossible the distinction
between platelets and MPs [25] and thus the accurate MP quantiﬁca-
tion, and iii) EDTA was added before the assay whereas this is not rec-
ommended for MP analysis since EDTA chelates calcium, a key actor
in the MP synthesis [26]. In addition, EDTA dissociates GpIIb-IIIa com-
plex [27] and is known to induce a P-selectin-dependent platelet activa-
tion process [28] that may result in pseudo-thrombopenia and platelet
aggregates on blood smears. Finally, EDTA tubes contain extremely
high concentration of potassium [29], whose impact on vesiculation
remains unknown. An advantage of the study of Lee et al. is that they
used washed platelets, giving potentially less false-negative results
than if it was performed in whole blood or in platelet-rich-plasma
(PRP) [5].
During the incubation of aHIT patient’s serumwith citrated 109 mM
whole blood froma healthy donor, PMPs expressing phosphatidylserine
are generated at low heparin concentration (1 IU UH/ml) due to the
formation of immune complexes (i.e. IgG-PF4-heparin). On the con-
trary, PMP rate decreases in presence of higher UH concentration
(500 IU UH/ml). This high concentration leads to a dissociation of the
complex Ig-PF4-Heparin and is therefore used to enhance the speciﬁcity
of all functional tests [2]. Consequently, we used a combination of ratio
between PMP annexin V positive concentration generated with 1 IU
UH/ml and 500 IU UH/ml (rule 1: ratio PMP PS+) and the concentra-
tion of PMPs annexin V positive generated at 1 IU UH/ml (rule 2: PMP
PS + concentration) to deﬁne one positive HIT (Fig. 1).
The 9 patients with clinical HIT were detected with the rule 1 of
PMPGA.IT patients with discordant PMPGA and SRA results.





- No HIT medical
- No HIT medical
+ (arterial) HIT medical
- HIT surgical
th) + (venous and arterial) HIT surgical
+ (venous) HIT medical
- HIT medical
+ (venous) HIT medical
+ (arterial) HIT medical
+ (venous) HIT medical
+ (venous) HIT medical
assay: A valuable test for immune heparin-induced thrombocytopenia
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5F. Mullier et al. / Thrombosis Research xxx (2013) xxx–xxxConsequently, the PMPGA is sufﬁcient sensitive to detect clinically
important HIT antibodies. Whereas AUC for “rule 1” and “rule
1 + rule 2” were not statistically different, the addition of rule 2 to
rule 1 allowed to suppress 1 false positive result in our series but led
to one false negative. A larger prospective study should be undertaken
to better characterize the usefulness of these 2 rules.
It is well recognized thatMP determination is affected by a variety of
pre-analytical and analytical variables [30–32]. We have previously
shown within-assay and between-assay variations of 18.6% and 30.5%,
respectively [15].
A limitation for performing of PMPGA is the immediate availability
of a healthy compatible blood group donor. Moreover, the choice of
the healthy subject inﬂuence the MP counts in the mix. Consequently,
each laboratory should theoretically determine its own cut-offs. To
overcome this difﬁculty, we proposed the use of ratios which are inde-
pendent of the MP counts of the healthy subject.
A PMP ratio between buffer (absence of heparin) and low heparin
concentration should be included in future investigations. To try to
increase the speciﬁcity of the study, blockade of Fc-receptor can also
be included.
By using a whole blood procedure, our test simulates the in vivo HIT
reaction and can be considered as easy to perform by avoiding platelet
washing. Consequently, PMPGA is a rapid assay with a turnaround
time (from sampling to ﬁnal result) of maximum 2 hours. But a disad-
vantage of whole blood as PRP-based procedures compared to washed
platelet assay, is the risk of suboptimal sensitivity for detecting HIT
antibodies [5].
Among patients with clinical HIT, there is 2 HIT without thrombosis,
5 with venous thrombosis and 2 with arterial thrombosis. The ability of
PMPGA to detect venous and arterial thrombosis was not addressed in
this study and may be an interesting perspective in the future.
The strengths of our study are the use of i) standardized clinical out-
comes to assess the performances of different assays [17], ii) FACS Aria I,
a validated instrument for large MV analysis [19] with a highly stable
ﬂow rate (between assay variation lower than 4%), and iii) calibrated
beads according to an international protocol for the standardization
and the validation of MPs analysis using FCM [19,20]. We have also
shown that no more than 2% of the PLT overlapped with the MPs gate
deﬁned on FSC with Mgx [25]. Nevertheless, it remains uncertain
whether the small-sized material seen in the ﬂow cytometric analysis
represents single or a swarm of PMPs [33], activated platelets or
immune complexes [34].
However, some limitations of the present study need to be
highlighted. First, the size of the cohort of patients is limited. The second
limitation in our study is the absence of a weak-positive control [5].
Multiple positive controls are described in the literature (Polyclonal an-
tibodies to PF4 (Hyphen), positive plasma from a known conﬁrmed HIT
patient [35], conﬁrmed anti-PF4-H platelet activating antibodies [36].
However, no international recommendation is currently available for
the use of positive controls.
We showed that PMPGA presented at least similar performances
than 14C-SRA. As ﬂow cytometry is more available and less time-
consuming than 14C-SRA and as it does not require radioactive material
contrary to 14C-SRA, PMPGA can be implemented in routine clinical
laboratories and may become a new promising biological reference to
diagnose HIT.Conclusion
PMPGA is a rapid and reliable assay mimicking in vivo HIT reaction.
In our sample of patients, PMPGA showed good correlation with
14C-SRA performances and predominately with clinical outcome. A
prospective study on a large cohort of suspected HIT patients
would be valuable to conﬁrm the use of PMPGA as a new promising
biological reference assay.Please cite this article as: Mullier F, et al, Platelet microparticle generation
diagnosis, Thromb Res (2013), http://dx.doi.org/10.1016/j.thromres.2013.Conﬂict of Interest Statement
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